Truist analyst David MacDonald upgraded Pennant Group (PNTG) to Buy from Hold with a price target of $34, up from $28. The upgrade reflects confidence in the company’s complementary business model, solid sector trends, favorable reimbursement outlook after a better-than-expected 2026 Home Health Final Rule, and strong M&A momentum highlighted by the Amedisys deal, the analyst tells investors in a research note. Financial flexibility remains solid, and the valuation is viewed as offering an attractive risk-reward profile, the firm says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG:
- Pennant Group upgraded to Buy from Hold at Truist
- Wells Fargo says CMS final rule positive for Pennant Group, BrightSpring Health
- CMS announces final rule for home health prospective payment system
- Amazon downgraded, Alphabet upgraded: Wall Street’s top analyst calls
- Wells upgrades Pennant Group on potential reimbursement upside